A benzoxazine derivative induces vascular endothelial cell apoptosis in the presence of fibroblast growth factor-2 by elevating NADPH oxidase activity and reactive oxygen species levels

Toxicology in Vitro

Volumn 23, Issue 6, 2009, Pages 1039-1046

  Zhao, Jing ^a,b   He, Qiuxia ^a,b   Cheng, Yizhe ^a,b   Zhao, Baoxiang ^a   Zhang, Yun ^b   Zhang, Shangli ^a,b   Miao, Junying ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

6,8 Dichloro 2,3 dihydro 3 hydroxymethyl 1,4 benzoxazine; Angiogenesis; Apoptosis; Nitric oxide; Reactive oxygen species

Indexed keywords

6,8 DICHLORO 2,3 DIHYDRO 3 HYDROXYMETHYL 1,4 BENZOXAZINE; BENZOXAZINE DERIVATIVE; FIBROBLAST GROWTH FACTOR 2; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; SIGNAL TRANSDUCTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

APOPTOSIS; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; NADPH OXIDASE; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; OXAZINES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; UMBILICAL VEINS;

EID: 68049083546     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.06.009     Document Type: Article

References (32)

1. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
2. Donnini S., and Ziche M. Constitutive and inducible nitric oxide synthase: role in angiogenesis. Antioxidants and Redox Signaling 4 (2002) 817-823
3. Folkman J. Fundamental concepts of the angiogenic process. Current Molecular Medicine 3 (2003) 643-651
4. Gavrieli Y., Sherman Y., and Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. The Journal of Cell Biology 119 (1992) 493-501
5. Ginnan R., Guikema B.J., Halligan K.E., Singer H.A., and Jourd'heuil D. Regulation of smooth muscle by inducible nitric oxide synthase and NADPH oxidase in vascular proliferative diseases. Free Radical Biology and Medicine 44 (2008) 1232-1245
6. Jaffe E.A., Nachman R.L., Becker C.G., and Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. The Journal of Clinical Investigation 52 (1973) 2745-2756
7. Jiao P.F., Zhao B.X., Wang W.W., He Q.X., Wan M.S., Shin D.S., and Miao J.Y. Design, synthesis, and preliminary biological evaluation of 2, 3-dihydro-3-hydroxymethyl-1,4-benzoxazine derivatives. Bioorganic and Medicinal Chemistry Letters 16 (2006) 2862-2867
8. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Medicine 6 (2000) 1004-1010
9. La D.S., Belzile J., Bready J.V., Coxon A., DeMelfi T., Doerr N., Estrada J., Flynn J.C., Flynn S.R., Graceffa R.F., Harriman S.P., Larrow J.F., Long A.M., Martin M.W., Morrison M.J., Patel V.F., Roveto P.M., Wang L., Weiss M.M., Whittington D.A., Teffera Y., Zhao Z., Polverino A.J., and Harmange J.C. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. Journal of Medicinal Chemistry 51 (2008) 1695-1705
10. Lamalice L., Le B.F., and Huot J. Endothelial cell migration during angiogenesis. Circulation Research 100 (2007) 782-794
11. Lechner M., Lirk P., and Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Seminars in Cancer Biology 15 (2005) 277-289
12. Li J.M., Mullen A.M., Yun S., Wientjes F., Brouns G.Y., Thrasher A.J., and Shah A.M. Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circulation Research 90 (2002) 143-150
13. Per-Hayta S., Ki-Sener E., Tekiner-Gulbas B., Yildiz I., Temiz-Arpaci O., Yalcin I., and Altanlar N. Synthesis, antimicrobial activity and QSARs of new benzoxazine-3-ones. Circulation Research 41 (2006) 1398-1404
14. Pipili-Synetos E., Kritikou S., Papadimitriou E., Athanassiadou A., Flordellis C., and Maragoudakis M.E. Nitric oxide synthase expression, enzyme activity and NO production during angiogenesis in the chick chorioallantoic membrane. British Journal of Pharmacology 129 (2000) 207-213
15. Price P., and McMillan T.J. Use of the tetrazolium assay in measuring the response of human tumor cells to ionizing radiation. Cancer Research 50 (1990) 1392-1396
16. RayChaudhury A., Frischer H., and Malik A.B. Inhibition of endothelial cell proliferation and bFGF-induced phenotypic modulation by nitric oxide. Journal of Cellular Biochemistry 63 (1996) 125-134
17. Ribatti D., Conconi M.T., and Nussdorfer G.G. Nonclassic endogenous novel [corrected] regulators of angiogenesis. Pharmacological Reviews 59 2 (2007) 185-205
18. Schwarzacher S.P., Lim T.T., Wang B., Kernoff R.S., Niebauer J., Cooke J.P., and Yeung A.C. Local intramural delivery of l-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation 95 (1997) 1863-1869
19. Segura I., Serrano A., De Buitrago G.G., Gonzalez M.A., Abad J.L., Claveria C., Gomez L., Bernad A., Martinez A., and Riese H.H. Inhibition of programmed cell death impairs in vitro vascular-like structure formation and reduces in vivo angiogenesis. The FASEB Journal 16 (2002) 833-841
20. Siemann D.W., Chaplin D.J., and Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004) 2491-2499
21. Smukste I., and Stockwell B.R. Advances in chemical genetics. Annual Review of Genomics and Human Genetics 6 (2005) 261-286
22. Spring D.R. Chemical genetics to chemical genomics: small molecules offer big insights. Chemical Society Reviews 34 (2005) 472-482
23. Suematsu N., Tsutsui H., Wen J., Kang D., Ikeuchi M., Ide T., Hayashidani S., Shiomi T., Kubota T., Hamasaki N., and Takeshita A. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107 (2003) 1418-1423
24. Suzuki K., Nakamura M., Hatanaka Y., Kayanoki Y., Tatsumi H., and Taniguchi N. Induction of apoptotic cell death in human endothelial cells treated with snake venom: implication of intracellular reactive oxygen species and protective effects of glutathione and superoxide dismutases. Journal of Biochemistry 122 (1997) 1260-1264
25. Tammariello S.P., Quinn M.T., and Estus S. NADPH oxidase contributes directly to oxidative stress and apoptosis in nerve growth factor-deprived sympathetic neurons. The Journal of Neuroscience 20 (2000) RC53
26. Tanaka Y., Moritoh Y., and Miwa N. Age-dependent telomere-shortening is repressed by phosphorylated alpha-tocopherol together with cellular longevity and intracellular oxidative-stress reduction in human brain microvascular endotheliocytes. Journal of Cellular Biochemistry 102 (2007) 689-703
27. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovascular Research 71 (2006) 226-235
28. Wang W., Liu X., Zhang Y., Zhao J., Zhao B., Zhang S., and Miao J. Both senescence and apoptosis induced by deprivation of growth factors were inhibited by a novel butyrolactone derivative through depressing integrin beta4 in vascular endothelial cells. Endothelium 14 (2007) 325-332
29. Zhao J., Miao J., Zhao B., and Zhang S. Upregulating of FAS, integrin beta4 and P53 and depressing of PC-PLC activity and ROS level in VEC apoptosis by safrole oxide. FEBS Letters 579 (2005) 5809-5813
30. Zhao J., Miao J., Zhao B., Zhang S., and Yin D. Suppressing Akt phosphorylation and activating Fas by safrole oxide inhibited angiogenesis and induced vascular endothelial cell apoptosis in the presence of fibroblast growth factor-2 and serum. The International Journal of Biochemistry and Cell Biology 38 (2006) 1603-1613
31. Zhao S.H., Berger J., Clark R.D., Sethofer S.G., Krauss N.E., Brothers J.M., Martin R.S., Misner D.L., Schwab D., and Alexandrova L. 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT6 receptor antagonists. Bioorganic and Medicinal Chemistry Letters 17 (2007) 3504-3507
32. Zhou D., Harrison B.L., Shah U., Andree T.H., Hornby G.A., Scerni R., Schechter L.E., Smith D.L., Sullivan K.M., and Mewshaw R.E. Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity. Bioorganic and Medicinal Chemistry Letters 16 (2006) 1338-1341